Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection.
about
Antiviral treatment for chronic hepatitis C in patients with human immunodeficiency virusApoptosis of uninfected cells induced by HIV envelope glycoproteinsKASL clinical practice guidelines: management of hepatitis CHepatitis C virus molecular evolution: transmission, disease progression and antiviral therapyPotential role of thymosin Beta 4 in liver fibrosisMicroRNAs, hepatitis C virus, and HCV/HIV-1 co-infection: new insights in pathogenesis and therapyEffect of serostatus for hepatitis C virus on mortality among antiretrovirally naive HIV-positive patientsHepatitis C virus infection in san francisco’s HIV-infected urban poorTherapeutic issues in HIV/HCV-coinfected patientsInfluence of increased CD4 cell counts on the genetic variability of hepatitis C virus in patients co-infected with human immunodeficiency virus IHCV Coinfection Associated with Slower Disease Progression in HIV-Infected Former Plasma Donors Naïve to ARTCoinfection with Hepatitis C Virus and Human Immunodeficiency Virus: Virological, Immunological, and Clinical OutcomesHigh levels of chronic immune activation in the T-cell compartments of patients coinfected with hepatitis C virus and human immunodeficiency virus type 1 and on highly active antiretroviral therapy are reverted by alpha interferon and ribavirin treaManaging chronic hepatitis C in the difficult-to-treat patientHepatitis C Virus (HCV) Quasispecies Complexity and Selection in HCV/HIV‐Coinfected Subjects Treated with Interferon‐Based RegimensTreat Early or Wait and Monitor? A Qualitative Analysis of Provider Hepatitis C Virus Treatment Decision-Making in the Context of HIV CoinfectionHIV/Hepatitis C Virus-Coinfected Virologic Responders to Pegylated Interferon and Ribavirin Therapy More Frequently Incur Interferon-Related Adverse Events Than Nonresponders DoBest strategies for global HCV eradication.Alcohol use disorder and its impact on chronic hepatitis C virus and human immunodeficiency virus infectionsHCV/HIV co-infection at a large HIV outpatient clinic in Sweden: feasibility and results of hepatitis C treatmentPeginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected personsDiagnosis, management, and treatment of hepatitis C: an updateIndian National Association for Study of the Liver (INASL) Guidance for Antiviral Therapy Against HCV Infection: Update 2016.Patient and provider characteristics associated with the decision of HIV coinfected patients to start hepatitis C treatment.Provider and patient correlates of provider decisions to recommend HCV treatment to HIV co-infected patientsIdentification of liver fibrosis in HIV/HCV-coinfected patients using a simple predictive model based on routine laboratory data.Reduced hepatitis B virus (HBV)-specific CD4+ T-cell responses in human immunodeficiency virus type 1-HBV-coinfected individuals receiving HBV-active antiretroviral therapy.Is antiretroviral therapy causing long-term liver damage? A comparative analysis of HIV-mono-infected and HIV/hepatitis C co-infected cohorts.Impaired quality of the hepatitis B virus (HBV)-specific T-cell response in human immunodeficiency virus type 1-HBV coinfectionMeta-analysis: increased mortality associated with hepatitis C in HIV-infected persons is unrelated to HIV disease progression.Pros and cons of liver transplantation in human immunodeficiency virus infected recipients.Acute Kidney Dysfunction in Patients with Chronic Hepatitis C Virus Infection: Analysis of Viral and Non-viral Factors.Liver test abnormalities in patients with HIV mono-infection: assessment with simple noninvasive fibrosis markersHepatitis C treatment experiences and decision making among patients living with HIV infection.Neurocognitive effects of HIV, hepatitis C, and substance use historyCan serum hyaluronic acid replace simple non-invasive indexes to predict liver fibrosis in HIV/Hepatitis C coinfected patients?Factors that influence an HIV coinfected patient's decision to start hepatitis C treatmentCocaine Use and Liver Disease are Associated with All-Cause Mortality in the Miami Adult Studies in HIV (MASH) Cohort.Relationships between cellular immune responses and treatment outcomes with interferon and ribavirin in HIV/hepatitis C virus co-infection.Prevalence and patient awareness of medical comorbidities in an urban AIDS clinic.
P2860
Q24240929-CBFAC693-0CC6-4458-A3F0-5DDD5F79F12EQ24801374-2615E366-37EB-4485-8B7E-BE3D804815E6Q26752471-73046666-1AEF-444C-A730-12102A0DDD2AQ26853500-0D65BBA5-DC01-4D8E-AAD5-8DAA7AB59F90Q27003833-E74242B3-A0A3-4E18-A885-BA1B3A1D789EQ27015778-AC1BF59D-F304-4C6A-B055-3AD3A24138D1Q27470167-FC158296-55D3-4AB9-B923-4192FEC10027Q27473306-C59B911C-99EC-487D-8375-F6B6B8438E78Q27481053-98D1C16E-2C1F-4ACB-8BA2-77AED5762BE4Q27485710-913A4AE1-EA03-445F-A838-7FA9DB37F304Q27487500-65158584-E059-4C9C-8C3A-182B4427DDBDQ27488883-9CF3570E-8841-4B88-9507-05BEE4D23E12Q27490328-A8BEBD0E-FEB0-4995-A119-2AC25B134BABQ27490409-364D9F5A-1964-4F25-A889-A315792E45B0Q27490972-6790EEF5-E6DD-4ADD-9924-0B1502FBAB96Q27491016-EE449D23-1E9E-46A4-BB3D-327573976A1BQ27491342-D509A867-CFD9-45D0-8CDF-0D4A71852CB2Q27693824-4F125792-5305-4096-A024-07CAE8BB7CECQ28070280-E8FEEBDA-F34A-4E74-A48C-A4AC47BC1F70Q28265090-9DCF219F-7A6A-4050-80A2-E5DFAA8EE366Q28274676-F8722E71-5E88-40D1-B9D4-3478A16DD0A3Q29619682-0F0E1464-C710-468F-BD80-69CFC053A1F2Q30355190-C7018543-26FC-4945-8175-03BF894C0694Q30405780-A3B1FA6F-631B-4AEA-9FD8-0957A43DAAC5Q30416486-51F9C4E0-F699-45D3-A72F-959AB15C726DQ31139499-1F484333-861E-4B3C-A8DA-F6C6290F2642Q33211869-A73C991B-468F-4D7F-974C-882D2CCCD31CQ33410098-8CA560B7-69AD-4BA4-9576-F37874E726F2Q33449162-7FECE734-5A29-4E7F-87D9-60824BF1E78AQ33585762-2894629A-96D4-480E-A26A-9B11C0AAD834Q33594879-3E69471A-98D4-4590-994B-B75B884DBFB5Q33595311-9EF9D958-A622-4DF3-9178-BE6B0A2535FEQ33621724-4EEE7BDB-8123-4AF8-91BC-02DE293A94F4Q33636377-9A28AF51-C9D9-4768-B4B0-9FCCA4A0E2A1Q33652957-738D2412-78A5-44F7-BF2B-DF0CF89D092DQ33665359-C0A35AB0-7D1E-4FCD-A6B2-72C028EE9BCDQ33705645-DBE73117-36D0-4724-A85A-6DA153D7C05AQ33712066-B5F29D03-63AB-44BB-A758-64A8AA9AA054Q33767267-034D2926-C2FB-410F-A198-9C47DB8FE6C5Q33810900-669C8B9E-895E-4FF9-AE17-20398C238688
P2860
Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
Increasing mortality due to en ...... unodeficiency virus infection.
@en
Increasing mortality due to en ...... unodeficiency virus infection.
@nl
type
label
Increasing mortality due to en ...... unodeficiency virus infection.
@en
Increasing mortality due to en ...... unodeficiency virus infection.
@nl
prefLabel
Increasing mortality due to en ...... unodeficiency virus infection.
@en
Increasing mortality due to en ...... unodeficiency virus infection.
@nl
P2093
P2860
P356
P1476
Increasing mortality due to en ...... unodeficiency virus infection.
@en
P2093
McGovern B
Snydman DR
P2860
P304
P356
10.1086/318501
P407
P577
2001-01-23T00:00:00Z